434 related articles for article (PubMed ID: 25906439)
1. Use of bevacizumab in recurrent glioblastoma.
Ghiaseddin A; Peters KB
CNS Oncol; 2015; 4(3):157-69. PubMed ID: 25906439
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma.
Lee EQ; Reardon DA; Schiff D; Drappatz J; Muzikansky A; Grimm SA; Norden AD; Nayak L; Beroukhim R; Rinne ML; Chi AS; Batchelor TT; Hempfling K; McCluskey C; Smith KH; Gaffey SC; Wrigley B; Ligon KL; Raizer JJ; Wen PY
Neuro Oncol; 2015 Jun; 17(6):862-7. PubMed ID: 25572329
[TBL] [Abstract][Full Text] [Related]
3. Bevacizumab: a treatment option for recurrent glioblastoma multiforme.
Buie LW; Valgus J
Ann Pharmacother; 2008 Oct; 42(10):1486-90. PubMed ID: 18765835
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab-induced hypertension is a predictive marker for improved outcomes in patients with recurrent glioblastoma treated with bevacizumab.
Zhong J; Ali AN; Voloschin AD; Liu Y; Curran WJ; Crocker IR; Shu HK
Cancer; 2015 May; 121(9):1456-62. PubMed ID: 25557543
[TBL] [Abstract][Full Text] [Related]
5. The Role of a Single Angiogenesis Inhibitor in the Treatment of Recurrent Glioblastoma Multiforme: A Meta-Analysis and Systematic Review.
Wang Y; Xing D; Zhao M; Wang J; Yang Y
PLoS One; 2016; 11(3):e0152170. PubMed ID: 27007828
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of recurrent glioblastoma with single-agent bevacizumab].
Sinkó D; Nemeskéri C
Orv Hetil; 2016 Mar; 157(13):500-3. PubMed ID: 26996897
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab in glioblastoma multiforme.
Specenier P
Expert Rev Anticancer Ther; 2012 Jan; 12(1):9-18. PubMed ID: 22149428
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma.
García-Romero N; Palacín-Aliana I; Madurga R; Carrión-Navarro J; Esteban-Rubio S; Jiménez B; Collazo A; Pérez-Rodríguez F; Ortiz de Mendivil A; Fernández-Carballal C; García-Duque S; Diamantopoulos-Fernández J; Belda-Iniesta C; Prat-Acín R; Sánchez-Gómez P; Calvo E; Ayuso-Sacido A
BMC Med; 2020 Jun; 18(1):142. PubMed ID: 32564774
[TBL] [Abstract][Full Text] [Related]
9. Different Timing to Use Bevacizumab in Patients with Recurrent Glioblastoma: Early
Pasqualetti F; Gonnelli A; Molinari A; Cantarella M; Montrone S; Cristaudo A; Baldaccini D; Mattioni R; Delishaj D; Mazzotti V; Morganti R; Cocuzza P; Fabrini MG; Lombardi G; Rudà R; Soffietti R; Paiar F
Anticancer Res; 2018 Oct; 38(10):5877-5881. PubMed ID: 30275213
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab for recurrent glioblastoma: a systematic review and meta-analysis.
Zhang T; Xin Q; Kang JM
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(21):6480-6491. PubMed ID: 34787852
[TBL] [Abstract][Full Text] [Related]
11. The role of bevacizumab in the treatment of glioblastoma.
Diaz RJ; Ali S; Qadir MG; De La Fuente MI; Ivan ME; Komotar RJ
J Neurooncol; 2017 Jul; 133(3):455-467. PubMed ID: 28527008
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma.
Field KM; Simes J; Nowak AK; Cher L; Wheeler H; Hovey EJ; Brown CS; Barnes EH; Sawkins K; Livingstone A; Freilich R; Phal PM; Fitt G; ; Rosenthal MA
Neuro Oncol; 2015 Nov; 17(11):1504-13. PubMed ID: 26130744
[TBL] [Abstract][Full Text] [Related]
13. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
14. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme.
Cohen MH; Shen YL; Keegan P; Pazdur R
Oncologist; 2009 Nov; 14(11):1131-8. PubMed ID: 19897538
[TBL] [Abstract][Full Text] [Related]
15. Phase II trial of ponatinib in patients with bevacizumab-refractory glioblastoma.
Lee EQ; Muzikansky A; Duda DG; Gaffey S; Dietrich J; Nayak L; Chukwueke UN; Beroukhim R; Doherty L; Laub CK; LaFrankie D; Fontana B; Stefanik J; Ruland S; Caruso V; Bruno J; Ligon K; Reardon DA; Wen PY
Cancer Med; 2019 Oct; 8(13):5988-5994. PubMed ID: 31444999
[TBL] [Abstract][Full Text] [Related]
16. Targeted therapy with bevacizumab and erlotinib tailored to the molecular profile of patients with recurrent glioblastoma. Preliminary experience.
D'Alessandris QG; Montano N; Cenci T; Martini M; Lauretti L; Bianchi F; Larocca LM; Maira G; Fernandez E; Pallini R
Acta Neurochir (Wien); 2013 Jan; 155(1):33-40. PubMed ID: 23132371
[TBL] [Abstract][Full Text] [Related]
17. ASCO 2013: bevacizumab and glioblastoma--a marriage dissolution?
Addeo R; Perri F; Parlato C; Della Vittoria G
Curr Med Res Opin; 2014 Sep; 30(9):1871-3. PubMed ID: 24803042
[TBL] [Abstract][Full Text] [Related]
18. Antivascular endothelial growth factor antibody for treatment of glioblastoma multiforme.
Hanson JA; Hsu FP; Jacob AT; Bota DA; Alexandru D
Perm J; 2013; 17(4):68-74. PubMed ID: 24361023
[TBL] [Abstract][Full Text] [Related]
19. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.
Pope WB; Kim HJ; Huo J; Alger J; Brown MS; Gjertson D; Sai V; Young JR; Tekchandani L; Cloughesy T; Mischel PS; Lai A; Nghiemphu P; Rahmanuddin S; Goldin J
Radiology; 2009 Jul; 252(1):182-9. PubMed ID: 19561256
[TBL] [Abstract][Full Text] [Related]
20. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
